1910-P: Increasing Adoption of Diabetes Technology among Adults with Type 1 Diabetes in a National Quality Improvement Collaborative: Results from Type 1 Diabetes Exchange

Résumé fourni par la source

Introduction and Objective: Advances in diabetes technology, including continuous glucose monitors (CGM) and automated insulin delivery systems (AID), have demonstrated significant benefits for glycemic outcomes and quality of life. Real-world adoption among adults with diabetes remains variable. The T1D Exchange Quality Improvement Collaborative (T1DX-QI) supports participating centers in implementing system-level interventions to increase access to diabetes technology Methods: Participating centers applied QI principles including the Ishikawa diagram, process map, effort/impact matrix tool, and Plan - Do - Study - Act cycles to test and expand interventions. Participating centers share monthly aggregate data with the coordinating center via a secure web portal. Aggregated data from January 2023 to May 2025 were analyzed. Statistical process control charts were used to assess trends in CGM use and AID use over time. Results: Adult CGM use increased from 69% to 77%, demonstrating sustained improvement and a shift in the mean. Adult AID use increased from 38% to 45%. Both CGM and AID utilization showed upward shifts, with multiple centers exceeding previous baselines Conclusion: Across the T1DX-QI Collaborative, CGM and AID use among adults has increased substantially over the past two years. These improvements align with coordinated QI efforts focused on workflow redesign, patient engagement, and reducing access barriers. Disclosure O. Odugbesan: None. T.R. Bol: None. T. Wright: None. H.K. Akturk: Consultant; Current; Roche, Medtronic, Dexcom, Inc. Research Support; Current; Roche, Abbott. K. Jones: Consultant; Current; Sanofi. G. Aleppo: Advisory Panel; Current; Medscape, Tandem Diabetes Care, Inc. Consultant; Current; Eli Lilly and Company, Dexcom, Inc., Insulet Corporation. Research Support; Current; AbbVie Inc., Bayer, Fractyl, Insulet Corporation, MannKind Corporation, Tandem Diabetes Care, Inc., Medtronic. J. Mathew: None. M. Zupa: None. C. Levy: Research Support; Current; Tandem Diabetes Care, Inc., Novo Nordisk, Abbott Diabetes, MannKind Corporation. Consultant; Current; MannKind Corporation, Tandem Diabetes Care, Inc. Research Support; Current; Deka/Sequel, Dexcom, Inc., Genti Bio. Consultant; Current; Deka/Sequel. E. Edmondson: Research Support; Current; American Diabetes Association. D. Broome: Research Support; Current; Sanofi, Fractyl Health, Inc., T1D Exchange, Rhythm Pharmaceuticals, Inc. Consultant; Current; Ono Pharmaceutical Co., Ltd. Research Support; Ended; Novo Nordisk. F. Joarder: None. M. Basina: None. M. El Muayed: Research Support; Current; Lilly. N. Rioles: None. N. Mathioudakis: None.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.